Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02174419 · ClinicalTrials.gov registry record · Phase 2
Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
A Phase 2 study of Prurigo Nodularis and Pruritus, sponsored by Trevi Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
- 4
- Study locations
NCT02174419 is a Phase 2 study of Prurigo Nodularis and Pruritus that has completed, run by Trevi Therapeutics. The registered enrollment target is 62 participants, below the 225-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (72% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT02174419, a Phase 2 study of Prurigo Nodularis and Pruritus, has completed, sponsored by Trevi Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
- 4
- Study locations
Study Summary
The primary objectives of the study are to evaluate the effects of two doses of nalbuphine HCl ER tablets on the change from baseline in the worst itch Numerical Rating Scale (NRS) in patients with prurigo nodularis and to evaluate the safety and tolerability in the study population.
Conditions Studied
Interventions
- DRUG nalbuphine HCl ER tablets 90 mg BID
- DRUG nalbuphine HCl ER tablets 180 mg BID
- DRUG Placebo tablets BID
Study Locations (4)
Ohio
- Case Western Reserve University - Cleveland
Pennsylvania
- Temple University Hospital - Philadelphia
Other
- University of Münster - Münster
Lower Silesian Voivodeship
- Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wroclawiu - Wroclaw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2015-03 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02174419
The ClinicalTrials.gov registry entry for NCT02174419 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 225-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (72% lower). The listed sponsor is Trevi Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Prurigo Nodularis appearing as the primary indexed condition, and to 3 interventions - of which nalbuphine HCl ER tablets 90 mg BID is the first listed.
NCT02174419 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Ohio, Pennsylvania, Other.
Frequently Asked Questions
What is clinical trial NCT02174419 about?
NCT02174419 is a clinical study titled "Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis". The primary objectives of the study are to evaluate the effects of two doses of nalbuphine HCl ER tablets on the change from baseline in the worst itch Numerical Rating Scale (NRS) in patients with prurigo nodularis and to evaluate the safety and tolerability in the study population.
What is the current status of trial NCT02174419?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2015-03. Estimated completion is 2016-08.
What conditions does trial NCT02174419 study?
This clinical trial studies the following conditions: Prurigo Nodularis, Pruritus, Nodularis Prurigo, Prurigo.
What interventions are being tested in trial NCT02174419?
The interventions under investigation include: nalbuphine HCl ER tablets 90 mg BID (DRUG), nalbuphine HCl ER tablets 180 mg BID (DRUG), Placebo tablets BID (DRUG).
Who is sponsoring clinical trial NCT02174419?
This trial is sponsored by Trevi Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02174419 being conducted?
This trial has 4 study locations across Ohio, Pennsylvania, Lower Silesian Voivodeship. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prurigo Nodularis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Barzolvolimab in Patients With Prurigo Nodularis
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Efficacy of CC-10004 for Prurigo Nodularis
COMPLETED · Phase 2
-
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
COMPLETED · Phase 2
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
RECRUITING · Phase 3
-
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
RECRUITING · Phase 3
-
Upadacitinib for Prurigo Nodularis
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.